NOXXON Pharma AG, a Berlin, Germany-based biotechnology company developing a promising new class of therapeutics called Spiegelmers, which are oligonucleotides made from the L-stereoisomer of RNA, has completed an additional €2m funding in its series D round.
This adds to the €33m raised in May 2010, and brings the total amount in this series D financing to €35m in aggregate.
New investors include CD Ventures and other private partners. They add to NGN Capital, TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft (DEWB), Seventure Partners, The Dow Chemical Company, Dieckell Group, Oppenheim Asset Management Services, IBG Risikokapitalfonds, VC Fonds Berlin, CD Ventures and others.
The company currently employs approximately 60 people.
FinSMEs
12/10/2010